How to Get Lantus (Insulin Glargine) in Arkansas

What Is Lantus and Why Is It Prescribed?

Insulin glargine is a long-acting basal insulin analog that provides up to 24 hours of relatively peakless glucose control. The FDA first approved Lantus (insulin glargine 100 U/mL, Sanofi) in April 2000, and the prescribing label documents its use in adults and pediatric patients (age 6 and older) with type 1 diabetes and in adults with type 2 diabetes [1]. A concentrated formulation, Toujeo (insulin glargine 300 U/mL), received separate FDA approval in 2015 [2].

The landmark ORIGIN trial (N=12,537) published in the New England Journal of Medicine in 2012 assigned people with dysglycemia to insulin glargine or standard care for a median of 6.2 years. Glargine reduced incident diabetes by 28% compared with standard care among pre-diabetic participants, and it did not increase cardiovascular events (hazard ratio 1.02 to 95% CI 0.94 to 1.11) [3]. That safety profile has made it one of the most widely prescribed basal insulins in the United States.

The American Diabetes Association's 2024 Standards of Care name basal insulin as a preferred intensification option when metformin plus lifestyle changes fail to keep A1C below the individualized target [4]. For many Arkansas patients, Lantus is the first injectable medication their physician recommends.

Prescribers Who Can Write a Lantus Prescription in Arkansas

Any state-licensed prescriber with a valid DEA number and the authority to manage endocrine conditions can prescribe Lantus in Arkansas. That includes:

• MDs and DOs licensed by the Arkansas State Medical Board
• Nurse Practitioners (APRNs) operating under AR Code Ann. § 17-87-310; Arkansas APRNs have full prescriptive authority after completing a collaborative practice requirement
• Physician Assistants (PAs) licensed under AR Code Ann. § 17-105-101, who prescribe under a supervising physician agreement

Endocrinologists at the University of Arkansas for Medical Sciences (UAMS) Diabetes Center and at private practices throughout Little Rock, Fayetteville, and Jonesboro routinely prescribe insulin glargine. Primary care physicians account for the majority of basal insulin prescriptions nationally, and Arkansas is no exception [5].

A 2023 CDC report found that 11.6% of Arkansas adults have diagnosed diabetes, the sixth-highest rate in the country [6]. That high burden means most primary care clinics in the state have substantial experience managing insulin-dependent patients.

Getting a Lantus Prescription Through Arkansas Telehealth

Arkansas explicitly authorizes telehealth prescribing of non-controlled medications under AR Code Ann. § 17-80-117 and the Arkansas Telehealth Act. Insulin glargine is not a controlled substance, so a licensed provider may issue a new Lantus prescription after a synchronous audio-video visit without an in-person examination, provided the visit meets the state's standard-of-care requirements.

The typical telehealth workflow for a new Lantus patient in Arkansas runs as follows:

1. Schedule a video visit with an Arkansas-licensed provider (in-state or via an interstate compact participating platform).
2. Complete pre-visit labs at a local draw site or through at-home finger-stick A1C kits accepted by some platforms. A1C and fasting glucose are the minimum; a comprehensive metabolic panel (CMP) is standard.
3. Attend the video visit. The provider reviews labs, confirms diagnosis, selects a starting dose (commonly 10 units once daily or 0.1 to 0.2 units/kg/day as recommended in ADA guidelines), and reviews injection technique via video [4].
4. Prescription transmitted electronically to the pharmacy of your choice, including mail-order options.
5. Follow-up titration visit typically within 2 to 4 weeks to adjust dose based on fasting glucose logs, targeting 80 to 130 mg/dL per ADA targets [4].

Most Arkansas-licensed telehealth platforms complete prescription transmission within 24 to 72 hours of the visit. Rural patients in counties such as Ashley, Chicot, and Lee, where endocrinologist access is sparse, find this pathway particularly valuable [6].

Telehealth is not appropriate for patients in diabetic ketoacidosis (DKA), those with severe hypoglycemia requiring glucagon, or those starting on a pump. Those cases require emergency or in-person care.

Labs Required Before a Lantus Prescription in Arkansas

No federal law mandates a specific lab panel before prescribing insulin glargine, but Arkansas community standards and ADA guidelines define a clear set of baseline tests [4]:

| Test | Why It Matters | Typical Reference Range | |------|---------------|------------------------| | Fasting plasma glucose | Confirms hyperglycemia and establishes baseline | <100 mg/dL normal | | Hemoglobin A1C | Quantifies 3-month glycemic burden | <5.7% normal | | Comprehensive metabolic panel (CMP) | Rules out renal and hepatic contraindications | eGFR >30 mL/min preferred | | Fasting lipid panel | Cardiovascular risk stratification | Per ACC/AHA targets | | Thyroid-stimulating hormone (TSH) | Type 1 workup; thyroid affects insulin sensitivity | 0.4 to 4.0 mIU/L | | C-peptide (type 1 suspected) | Distinguishes insulin deficiency from resistance | <0.6 ng/mL suggests deficiency | | GAD-65 antibodies (type 1 suspected) | LADA/type 1 confirmation | Negative in type 2 |

The ADA's 2024 Standards of Care recommend measuring A1C at least twice yearly in stable patients and quarterly when regimen changes are made [4]. Quest Diagnostics and LabCorp both operate patient service centers in Little Rock, Fayetteville, Fort Smith, and Texarkana, AR, making lab access reasonably straightforward for most state residents.

Arkansas Medicaid and Insurance Coverage for Lantus

Arkansas Medicaid (Arkansas Works / ARHOME)

Arkansas Medicaid covers insulin glargine for both type 1 and type 2 diabetes, but the drug sits on a tier that requires prior authorization (PA) for most beneficiaries. The standard PA criteria mirror those used by many state Medicaid programs:

• Confirmed diagnosis of type 1 or type 2 diabetes mellitus (ICD-10 E10.x or E11.x)
• Documentation that the patient is not controlled on intermediate-acting insulin (NPH) or that NPH is contraindicated (e.g., nocturnal hypoglycemia episodes)
• Prescriber attestation of medical necessity

Standard PA review runs 3 to 5 business days. Expedited review for urgent clinical need must be resolved within 24 hours under federal Medicaid managed care rules [7]. If denied, patients have 90 days to file a formal appeal under Arkansas DHS guidelines.

A 2022 analysis in JAMA Internal Medicine found that insulin prior authorization processes delayed therapy initiation by a median of 14 days across U.S. state Medicaid programs, with rural patients facing the longest delays [8].

Commercial Insurance

Most commercial plans in Arkansas (Arkansas Blue Cross, QualChoice, Ambetter) place Lantus on Tier 3 of their formularies. Copays range from $40 to $100 per month with in-network pharmacies. Toujeo (glargine 300 U/mL) and biosimilar glargine products such as Semglee (approved by FDA as interchangeable) [9] may appear on lower tiers and are clinically equivalent for most patients.

Uninsured Patients

Sanofi's Insulins Valyou Savings Program caps out-of-pocket cost at $99 per 30-day supply for uninsured adults [10]. GoodRx pricing at major Arkansas chains (Walmart, Walgreens, CVS, Kroger) ranges from approximately $75 to $160 per vial of Lantus 100 U/mL depending on the specific pharmacy and coupon applied. Walmart's private-label ReliOn insulin (70/30 and NPH, not glargine) is not a therapeutic substitute for Lantus without physician guidance.

Where to Fill a Lantus Prescription in Arkansas

Retail Chains

Walmart, Walgreens, CVS, and Kroger pharmacies operate across Arkansas and accept most commercial and Medicaid plans. Walgreens in particular has 24-hour locations in Little Rock and Fayetteville useful for after-hours insulin access.

Independent and Compounding Pharmacies

Arkansas 503A compounding pharmacies are licensed by the Arkansas State Board of Pharmacy and may prepare compounded insulin formulations for patients with documented clinical need for a non-commercially available concentration or delivery form. The FDA's guidance on compounded insulin products specifies that commercially available insulin glargine should be used when accessible, and compounded versions are reserved for cases where the commercial product does not meet the patient's medical needs [11]. Any 503A pharmacy compounding insulin in Arkansas must follow USP <797> sterile compounding standards.

Mail-Order and Specialty Pharmacies

Express Scripts, CVS Caremark, and OptumRx all ship insulin glargine to Arkansas addresses. Mail-order typically provides a 90-day supply at lower per-unit cost. Cold-chain shipping is used; Lantus should be stored in the refrigerator at 36 to 46°F until opened, after which it is stable at room temperature (<86°F) for 28 days [1].

Telehealth-Affiliated Pharmacies

Several direct-to-patient telehealth pharmacies (e.g., Alto, Amazon Pharmacy) accept Arkansas addresses and can receive electronic prescriptions from any in-state or telehealth provider with an Arkansas license, offering home delivery within 1 to 3 business days.

Step-by-Step: How to Get Lantus in Arkansas

The following sequence applies whether you are starting insulin for the first time or transferring an existing prescription.

Step 1. Confirm your diagnosis documentation. Locate your most recent A1C result and any prior diabetes visit notes. Providers need this to justify PA and to calibrate your starting dose.

Step 2. Choose a prescriber pathway. In-person primary care or endocrinology takes 1 to 4 weeks for a new-patient appointment in most Arkansas metro areas; telehealth visits are typically available within 24 to 48 hours.

Step 3. Complete labs. Order or confirm the panel listed in the section above. Results must reach the provider before or during the visit.

Step 4. Attend the visit and receive your prescription. E-prescriptions transmit directly to your chosen pharmacy. Confirm the pharmacy has the 100 U/mL vials or pens you need; Toujeo SoloStar pens may require a separate stock order at smaller independent pharmacies.

Step 5. Address insurance. If your plan requires PA, ask the prescriber's office to submit PA documentation the same day as your visit. Some telehealth platforms automate PA submission.

Step 6. Apply cost programs. Present the Sanofi Insulins Valyou card or GoodRx coupon at the pharmacy if your plan does not cover the cost adequately.

Step 7. Schedule titration follow-up. Log fasting glucose readings daily. The ADA's "2 in 3" titration rule advises increasing the glargine dose by 2 units every 3 days when fasting glucose consistently exceeds 130 mg/dL [4].

Transferring an Existing Lantus Prescription to Arkansas

Patients relocating to Arkansas from another state can transfer a retail pharmacy prescription to any Arkansas pharmacy in the same chain or to an independent pharmacy. Arkansas pharmacists may transfer a prescription once between pharmacies; controlled substances require the originating pharmacy to void the original. Because insulin glargine is non-controlled, transfers are straightforward.

If the original prescription has no refills remaining, the receiving Arkansas pharmacist may dispense an emergency supply (typically 72 hours) under the Arkansas Board of Pharmacy's emergency dispensing rules while you arrange a new prescription from an Arkansas-licensed provider.

The National Association of Boards of Pharmacy (NABP) maintains a database of state-licensed pharmacies that can assist in verifying the legitimacy of mail-order pharmacies for patients who wish to continue using an out-of-state mail-order service after relocating [12].

Dosing and Safety Essentials for Arkansas Patients

Insulin glargine is not interchangeable unit-for-unit with NPH insulin. A patient switching from twice-daily NPH (e.g., 30 units morning, 30 units evening) to once-daily glargine typically starts at 80% of the total daily NPH dose (48 units of glargine once daily at bedtime) per the Lantus FDA label [1].

Key safety points that Arkansas prescribers and pharmacists routinely cover:

• Hypoglycemia is the most common adverse effect. The prescribing information reports symptomatic hypoglycemia in 3 to 32% of patients in clinical trials depending on diabetes type and monitoring intensity [1].
• Injection site rotation prevents lipohypertrophy. The abdomen, thigh, and upper arm are all acceptable sites.
• Never dilute or mix glargine with any other insulin in the same syringe; precipitation occurs and alters pharmacokinetics [1].
• Biosimilar interchangeability. The FDA has designated Semglee (glargine-yfgn, Biocon/Viatris) as interchangeable with Lantus [9]. Arkansas pharmacists may substitute Semglee without a new prescription unless the prescriber writes "Dispense as Written."

The ORIGIN trial also evaluated whether long-term glargine use increased cancer risk, a concern raised in early observational data. The 6.2-year median follow-up found no significant difference in cancer incidence between glargine and standard care (HR 1.00 to 95% CI 0.88 to 1.13) [3].

Prior Authorization: What Arkansas Providers Must Document

The Arkansas Medicaid PA process for Lantus requires a clinical submission from the prescribing provider. The dossier typically includes:

1. Diagnosis code (E10.x for type 1; E11.x for type 2)
2. Most recent A1C value and date
3. Current antidiabetic regimen and duration
4. Clinical rationale for glargine over NPH (e.g., documented nocturnal hypoglycemia, occupational constraints on twice-daily injections, or inadequate control on NPH)
5. Prescriber's name, NPI, and Arkansas license number

The American Diabetes Association has formally stated, in its 2024 Standards of Care: "Prior authorization and step therapy protocols can impede access to necessary diabetes medications and should be minimized by payers." [4] That statement is often cited in PA appeal letters to Arkansas Medicaid managed care organizations.

A 2021 study in Diabetes Care (N=4,211 type 1 patients) found that patients subject to insulin PA requirements had a 23% higher rate of emergency department visits for hypoglycemia compared with patients without PA requirements, suggesting that delays in basal insulin access carry direct clinical risk [13].

Frequently Asked Questions